bevacizumab + liposomal irinotecan + 5-fluorouracil + leucovorin

This combination regimen is a multi-agent chemotherapy and targeted therapy protocol consisting of bevacizumab, liposomal irinotecan, 5-fluorouracil (5-FU), and leucovorin. It is currently being investigated in the Phase II IRIS trial (NCT06184698) as a second-line treatment for patients with metastatic colorectal cancer who have progressed on oxaliplatin-based first-line therapy. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis. Liposomal irinotecan is a nanoliposomal formulation of the topoisomerase I inhibitor irinotecan, designed to enhance drug delivery to tumor tissues while reducing systemic toxicity. 5-FU is an antimetabolite that inhibits thymidylate synthase, and leucovorin is administered to potentiate the cytotoxic effects of 5-FU. Preliminary clinical data suggest that this combination offers encouraging activity with a manageable safety profile in the advanced colorectal cancer setting.

Brand names

DuoendaAvastin

Other names

bevacizumab + irinotecan liposome + 5-FU/LVbevacizumab + nal-IRI + 5-FU/LV